Announcement on the FDA Approval of Cipepofol Injection

Haisco Pharmaceutical Group Co., Ltd.·June 1, 2026·3 pages

✨ AI Summary

Haisco Pharmaceutical Group's subsidiary, Haisco-USA, has received FDA approval for Cipepofol Injection, a new drug for adult general anesthesia induction. This marks a significant milestone as it is the first self-innovated intravenous anesthetic from China to gain FDA approval. The company aims to expand its global market presence and anticipates new revenue growth from this approval.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Haisco Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company") announces that its wholly-owned subsidiary, Haisco-USA Pharmaceuticals Inc., has recently received notification of FDA approval for the marketing of Cipepofol Injection (English generic name: Cipepofol Injection, Chinese trade name: 思舒宁®, English trade name: CYPSEDO). This product is approved for adult general anesthesia induction.

1. Basic Information of the Drug

Drug Name: Cipepofol Injection (CYPSEDO)
Application Type: NDA
Dosage Form: Injection
Specification: 50mg:20ml
Indication: Induction of general anesthesia in adults undergoing surgery

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.